Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Yellowknifer69on Mar 31, 2020 1:37am
399 Views
Post# 30862916

Re: Corporate Leveraging

Re: Corporate LeveragingHello and good mornin' fellow Antibe holders:

Just finishing up for the day - yes that is a 17 hour day working on planning for what comes next in the world of Covid-19.

so just catching up on this awesome bullboard (thanks to regular contributions from QWERTY and MUGS)!  So as a corporate leader and investor I thought I would share the link below.  Why?

Because both Antibe and any potential investor (i.e Gilead, Bayer) are going to be carefully reviewing their products, pipelines, and how to leverage assets in a time of fiscally volatile times.

Key points are:

1. focus on core assets - R&D are critical to this (big Pharm still has to feed the pipeline
2. Remain generous - philanthropy still matters
3. Demonstrate Compassion - Speaks for itself.
4. Systems solutions - a non-addictive NSAID will be a game changer in the system

https://www.fsg.org/blog/covid-19-and-corporate-purpose%E2%80%94four-ways-businesses-can-respond-now

Anyways. I thought this was a worthy read given that we are close to some company disclosure of results.

Praying for you all in the United States and across Canada,

Yellowknifer,

P.S Single malt scotch is a great way to relieve your day to day stress for an hour or two.  

Bullboard Posts